0
0
British researchers are confident that Phase III study will yield positive results.
With regard to the vaccine co-developed by Oxford researcher Sarah Gilbert, called AZD1222 against Covid-19, the team announced current results for the course of the Phase III study for the next few days, writes the British newspaper The Independent.
Gilbert already said in The Independent that the latest results show high efficacy. Hopes were high that the vaccine could soon be presented to health officials and would then be available by the end of the year. The pharmaceutical company AstraZeneca, which cooperates with Oxford University, plans to produce two billion vaccine doses by summer 2021.
The vaccine is currently being tested on thousands of volunteers in the UK, South Africa, Brazil and the USA.
Other promising vaccines
In addition to the Oxford vaccine, other promising vaccines are currently under development. Gilbert is confident that many of these will deliver positive results. “In some of them, we see a good level of antibody neutralization, in some of them a strong immune response.”
If this works, other vaccines will work as well. “We expect that there will be several vaccines.
However, the researcher also admits that it is currently “difficult” to say how long the protection of the AZD 1222 vaccine will last and what immune status can be achieved with it.
— Hector Pascua, Source: The Independent, Picture: stockilyapp.com
This post has already been read 818 times!
